AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21784084 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from laser head to skin at 20 cm
Number of subjects: 11
Study 21784084 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from laser head to skin at 30 cm
Number of subjects: 11
Study 21784084 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from laser head to skin (10-30 cm interval)
Number of subjects: 11
Study 19563191 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection at acupoint combined with warming needle therapy
Number of subjects: 197
Study 19563191 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 197
Study 17984151 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (10 weekly sessions, 15-30 minutes each over three months)
Number of subjects: 12
Study 17984151 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coaching intervention)
Number of subjects: 12
Study 14624393 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine with added plant sterols
Number of subjects: 42
Study 14624393 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA margarine
Number of subjects: 42
Study 14624393 — intervention group
Group type: COMPARATOR
Intervention: Both types of margarine
Number of subjects: 42
Study 11199374 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 40
Study 11199374 — intervention group
Group type: COMPARATOR
Intervention: Procaine
Number of subjects: 40
Study 9166032 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% sucrose
Number of subjects: 19
Study 9166032 — intervention group
Group type: COMPARATOR
Intervention: distilled water (placebo)
Number of subjects: 19
Study 8260371 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin 2 (rIL-2) 120 h continuous infusion at 18 x 10(6) iu m‐2 day followed by three injections of 5FU 600 mg m‐2 at weekly intervals
Number of subjects: 16
Study 8260371 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 5FU (after initial treatment with rIL-2)
Number of subjects: 16
Study 3978007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl continuous i.v. infusion at 1.5 microgram kg‐1 min‐1
Number of subjects: 0
Study 3978007 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl continuous i.v. infusion at 0.5 microgram kg‐1 min‐1
Number of subjects: 0
Study 3978007 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 29350276 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming exercise
Number of subjects: 70
Study 29350276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no swimming exercise)
Number of subjects: 70
Study 25730290 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) - single dose of 10 units per kilogram body weight
Number of subjects: 125
Study 25730290 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 125
Study 25730290 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 125
Study 25436661 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (PPT insoles for 30 days, then silicone orthosis for toes for another 30 days)
Number of subjects: 24
Study 25436661 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (PPT insoles and silicone orthosis for 30 days, then only insoles for another 30 days)
Number of subjects: 24
Study 25436661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 24
Study 22591059 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up treatment strategy (antacid 4dd + placebo 1dd)
Number of subjects: 653
Study 22591059 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down treatment strategy (proton pump inhibitor 1dd + placebo 4dd)
Number of subjects: 653
Study 22591059 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 3 (five pills/day, placebo and verum vice versa from step 1)
Number of subjects: 653
Study 22591059 — intervention group
Group type: COMPARATOR
Intervention: Active medication vs. placebo
Number of subjects: 653
Study 22591059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake fidelity errors
Number of subjects: 653
Study 20732526 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake group (thoracic epidural anesthesia and spontaneous ventilation)
Number of subjects: 50
Study 20732526 — intervention group
Group type: COMPARATOR
Intervention: Control group (general anesthesia with one-lung ventilation)
Number of subjects: 50
Study 18950330 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (2 mcg x kg(‐1)) and infraorbital nerve block with 0.5 ml preservative-free normal saline on each side
Number of subjects: 46
Study 18950330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital nerve blocks with 0.5 ml on each side of 0.25% bupivacaine and 2 ml of preservative-free saline solution intravenously
Number of subjects: 46
Study 16192766 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid crystalloid infusion (group 1)
Number of subjects: 112
Study 16192766 — intervention group
Group type: COMPARATOR
Intervention: Minimal maintenance rate crystalloid infusion (group 0)
Number of subjects: 112
Study 16192766 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal outcome
Number of subjects: 112
Study 16192766 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal side effects
Number of subjects: 112
Study 12814476 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (0.25 to 3.5 mg)
Number of subjects: 24
Study 10385641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment for 4 weeks
Number of subjects: 25
Study 10385641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment for 2 years
Number of subjects: 25
Study 10385641 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 8610601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 1735
Study 8610601 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 1735
Study 1802393 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg NGT
Number of subjects: 20
Study 1802393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6828256 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous suspension of cofosfolactamines
Number of subjects: 5
Study 6828256 — intervention group
Group type: COMPARATOR
Intervention: Tablets of cofosfolactamines
Number of subjects: 5
Study 29850450 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil group (receiving 20% of total daily energy from olive oil)
Number of subjects: 50
Study 29850450 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal consumption of oil)
Number of subjects: 50
Study 29850450 — intervention group
Group type: COMPARATOR
Intervention: Comparison between olive oil group and control group
Number of subjects: 50
Study 27267431 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro administered by QS-M needle-free jet injector
Number of subjects: 18
Study 24598007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide nasal aerosol (CIC-HFA) 74-μg (37 μg/spray, 1 spray/each nostril)
Number of subjects: 14
Study 24598007 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate monohydrate aqueous nasal spray (MFNS) 200-μg (50 μg/spray, 2 sprays/each nostril)
Number of subjects: 14
Study 22374626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (cognitive therapy)
Number of subjects: 50
Study 22374626 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic desensitization (behavioral therapy)
Number of subjects: 50
Study 21046771 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide and Pingyangmycin
Number of subjects: 29
Study 21046771 — intervention group
Group type: COMPARATOR
Intervention: Pingyangmycin only
Number of subjects: 29
Study 18323413 — intervention group
Group type: EXPERIMENTAL
Intervention: Total estradiol
Number of subjects: 153
Study 18323413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailable estradiol
Number of subjects: 153
Study 18323413 — intervention group
Group type: EXPERIMENTAL
Intervention: Free estradiol
Number of subjects: 153
Study 18323413 — intervention group
Group type: COMPARATOR
Intervention: Total estradiol concentration comparison
Number of subjects: 153
Study 18323413 — intervention group
Group type: COMPARATOR
Intervention: Testosterone and sex hormone binding globulin
Number of subjects: 153
Study 16555489 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-based tool for evaluating protocol quality
Number of subjects: 64
Study 16555489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 11818522 — intervention group
Group type: COMPARATOR
Intervention: Low fatty acid amide hydrolase (FAAH) activity in lymphocytes of IVF-embryo transfer patients who failed to achieve an ongoing pregnancy (46 +/- 17 pmol/min per mg protein)
Number of subjects: 0
Study 11818522 — intervention group
Group type: COMPARATOR
Intervention: Increased blood anandamide (AEA) levels in patients who failed to achieve an ongoing pregnancy (4.0 +/- 2.2 pmol/ml)
Number of subjects: 0
Study 11818522 — intervention group
Group type: COMPARATOR
Intervention: No difference in blood levels of 2-arachidonoylglycerol or N-palmitoylethanolamine between pregnant and nonpregnant women
Number of subjects: 0
Study 11818522 — intervention group
Group type: COMPARATOR
Intervention: No difference in the activity of the AEA membrane transporter or amounts of cannabinoid receptors in lymphocytes between groups
Number of subjects: 0
Study 10608579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concordance status (<50%)
Number of subjects: 333
Study 10608579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concordance group
Number of subjects: 333
Study 10608579 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between parents and youth
Number of subjects: 333
Study 7782055 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH)
Number of subjects: 8
Study 7782055 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 8
Study 2117147 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TNS)
Number of subjects: 311
Study 2117147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 7032697 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (A)
Number of subjects: 16
Study 7032697 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (N)
Number of subjects: 16
Study 7032697 — intervention group
Group type: EXPERIMENTAL
Intervention: association of acebutolol and nifedipine (A+N)
Number of subjects: 16
Study 7032697 — intervention group
Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 16
Study 31711499 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIMMER lifestyle intervention
Number of subjects: 316
Study 31711499 — intervention group
Group type: COMPARATOR
Intervention: Usual health care
Number of subjects: 316
Study 28679476 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous autologous bone marrow aspirate instillation at fracture site along with cannulated cancellous screw fixation
Number of subjects: 32
Study 28679476 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and cannulated cancellous screw fixation (control)
Number of subjects: 32
Study 26204331 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose olprinone continuously infused for 24 hours starting just before anesthesia induction
Number of subjects: 40
Study 26204331 — intervention group
Group type: COMPARATOR
Intervention: Placebo continuously infused for 24 hours starting just before anesthesia induction
Number of subjects: 40
Study 26204331 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose olprinone
Number of subjects: 40
Study 26204331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23709289 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (3 mg/kg) before passive heat loading (PHL)
Number of subjects: 9
Study 21251076 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (0.5%)
Number of subjects: 29
Study 21251076 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 29
Study 19766056 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 8
Study 24683674 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Sprinkles (12.5 mg of elemental iron, n = 79)
Number of subjects: 136
Study 24683674 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly Sprinkles (30 mg of elemental iron, n = 73)
Number of subjects: 136
Study 24683674 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 136
Study 15342807 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human leptin treatment for up to three months
Number of subjects: 14
Study 15342807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 14
Study 15342807 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human leptin treatment
Number of subjects: 14
Study 11253161 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day
Number of subjects: 179
Study 11253161 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 179
Study 11253161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 10759276 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 71
Study 10759276 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 71
Study 9200286 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (0.25 pmol/kg/min)
Number of subjects: 8
Study 9200286 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY (0.25 pmol/kg/min)
Number of subjects: 8
Study 9200286 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (0.5 pmol/kg/min)
Number of subjects: 8
Study 9200286 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY (0.5 pmol/kg/min)
Number of subjects: 8
Study 9200286 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and PYY combined (0.25 pmol/kg/min each)
Number of subjects: 8
Study 9200286 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and PYY combined (0.5 pmol/kg/min each)
Number of subjects: 8
Study 1338742 — intervention group
Group type: EXPERIMENTAL
Intervention: Live enterovirus oral vaccines, administered in 2-3 doses at intervals of 7-10 days.
Number of subjects: 150000
Study 1338742 — intervention group
Group type: COMPARATOR
Intervention: Nonimmunized subjects (control group).
Number of subjects: 150000
Study 4014743 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 139
Study 4014743 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or more mg of morphine
Number of subjects: 139
Study 4014743 — intervention group
Group type: COMPARATOR
Intervention: 0 mg morphine (control)
Number of subjects: 139
Study 4014743 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg morphine
Number of subjects: 139
Study 31199765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh coconut (100 g daily)
Number of subjects: 0
Study 31199765 — intervention group
Group type: COMPARATOR
Intervention: Groundnut and groundnut oil
Number of subjects: 0
Study 29516702 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance acupuncture combined with motor relearning training
Number of subjects: 62
Study 29516702 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture combined with motor relearning training
Number of subjects: 62
Study 26865472 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (BTDS) 5 mg
Number of subjects: 3
Study 26865472 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (BTDS) 10 mg
Number of subjects: 3
Study 26865472 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal delivery system (BTDS) 20 mg
Number of subjects: 3
Study 26865472 — intervention group
Group type: COMPARATOR
Intervention: Intravenous buprenorphine infusion
Number of subjects: 3
Study 24828298 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVAsol + isotretinoin (0.5 mg/kg/day)
Number of subjects: 40
Study 24828298 — intervention group
Group type: COMPARATOR
Intervention: PUVAsol only (control group)
Number of subjects: 40
Study 22031045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulator (HFS)
Number of subjects: 16
Study 22031045 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity simulator (LFS)
Number of subjects: 16
Study 20538183 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Term Life Review interview
Number of subjects: 68
Study 18588452 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0
Study 18588452 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 0
Study 15921865 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.625/2.5 mg daily for 24 weeks
Number of subjects: 1028
Study 15921865 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.45/1.5 mg daily for 24 weeks
Number of subjects: 1028
Study 15921865 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA) 0.3/1.5 mg daily for 24 weeks
Number of subjects: 1028
Study 11938636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterioss (test group)
Number of subjects: 48
Study 11938636 — intervention group
Group type: COMPARATOR
Intervention: Sterioss (control group)
Number of subjects: 48
Study 11938636 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern Implants (test group)
Number of subjects: 48
Study 11938636 — intervention group
Group type: COMPARATOR
Intervention: Southern Implants (control group)
Number of subjects: 48
Study 10190531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil therapy for 2 weeks
Number of subjects: 0
Study 10190531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8544891 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests ordered by multiple physicians
Number of subjects: 1500
Study 2253292 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 10-15 micrograms.kg-1 (Group I)
Number of subjects: 105
Study 2253292 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms.kg-1 (Group II)
Number of subjects: 105
Study 2253292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 105
Study 30993861 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin 50 mg daily
Number of subjects: 0
Study 30993861 — intervention group
Group type: COMPARATOR
Intervention: metformin 1000-1500 mg daily
Number of subjects: 0
Study 30993861 — intervention group
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Number of subjects: 0
Study 30993861 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 0
Study 27990626 — intervention group
Group type: EXPERIMENTAL
Intervention: Banking Time
Number of subjects: 470
Study 27990626 — intervention group
Group type: EXPERIMENTAL
Intervention: Child time
Number of subjects: 470
Study 27990626 — intervention group
Group type: COMPARATOR
Intervention: Business as usual (BAU)
Number of subjects: 470
Study 25588587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous high single-dose of iron isomaltoside 1000 (1,200 mg)
Number of subjects: 200
Study 25588587 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 200
Study 24114290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% topical sodium lauryl sulfate (SLS)
Number of subjects: 8
Study 24114290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% topical sodium lauryl sulfate (SLS)
Number of subjects: 8
Study 24114290 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical sodium lauryl sulfate (SLS)
Number of subjects: 8
Study 24114290 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical sodium lauryl sulfate (SLS)
Number of subjects: 8
Study 24114290 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry (LDF)
Number of subjects: 8
Study 24114290 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler imaging (LDI)
Number of subjects: 8
Study 24114290 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study 21301830 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty
Number of subjects: 120
Study 21301830 — intervention group
Group type: COMPARATOR
Intervention: Unipolar hemiarthroplasty
Number of subjects: 120
Study 21301830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular erosion
Number of subjects: 120
Study 19132712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (10 mg/day for 3 days, 20 mg/day for 3 days, then 30 mg/day for 8 days)
Number of subjects: 18
Study 17143605 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1160
Study 17143605 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1160
Study 15220020 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 212
Study 15220020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen 5/325 mg
Number of subjects: 212
Study 15220020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 11521984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 4 weeks
Number of subjects: 563
Study 11521984 — intervention group
Group type: COMPARATOR
Intervention: Cisapride 10 mg bid for 4 weeks
Number of subjects: 563
Study 9630109 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 216
Study 9630109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 9630109 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal proANF
Number of subjects: 216
Study 9630109 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate changes
Number of subjects: 216
Study 8140872 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 24